RNA sequencing of sorted control CD4+ T-cells and TCRVbeta8+ T-cell lymphoma cells from mouse spleens
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB51835 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:We evaluate differential gene expression in 6 cases of canine CD4+ peripheral T-cell lymphoma (PTCL) compared to sorted CD4+ lymphocytes from the lymph nodes of healthy dogs.Lymph node aspirates from 6 dogs submited for routine diagnostics and diagnosed with CD4+ PTCL by flow cytometry were selected for RNA-seq. Patients were naïve to treatment at the time of sample submission. Aspirates from selected cases had a purity of greater than 88% neoplastic cells. Neoplastic cells were identified by the following immunophenotype: CD4+CD3+CD5+/-CD45+MHCIIlo. Hierarchical clustering of samples resulted in distinct separation of control lymphocytes and PTCL cases with intermixing of PTCL from Boxer and non-Boxer dogs. Top enriched pathways are involved in G-coupled protein receptor signaling, extracellular matrix remodeling and vascular development, inflammatory response and immune signaling, and mitotic activity. This study provides the global gene expression analysis of aggressive canine T-cell lymphoma using RNAsequencing.
2018-11-09 | GSE122347 | GEO
Project description:Early events mediated by cancer progression remain relative unknown. Here, we provide analysis of CD4 T cells derived from C57Bl/6 mice transplanted with Eu-Myc lymphoma cells at earlyand late time points versus CD4 T cells derived from non-tumor-bearing control mice. Our data indicate that CD4 T-cell differentiation and fate is not provoked until late in tumor growth. These studies demonstrate when CD4 T-cell gene expression might change in the course of lymphoma progression.
2022-07-15 | GSE183693 | GEO
Project description:Global gene expression changes in canine CD4+ peripheral T-cell lymphoma
| PRJNA504672 | ENA
Project description:Tumor-infiltrating regulatory T cells contribute to an immunosuppressive tumor microenvironment. We applied single-cell RNA sequencing (scRNA-seq) , TCR sequencing combined with cellular indexing of transcriptomes and epitopes (CITE-seq) on CD4 T cells to decipher the heterogeneity of intratumoral Tregs in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), compared with non-malignant tonsillar tissue.
2023-09-12 | GSE242756 | GEO
Project description:TET2 is an enzyme for converting methylcytosine (mC) to hydorxymethylcytosine (hmC) and its mutations have been frequently found in myeloid malignancies and T-cell lymphoma in humans. We analyzed Tet2 gene trap mice and found that homozygous mice developed T-cell lymphoma with follicular helper T-cell-like features. To examine comprehensive gene expression patterns of lymphoma cells, We performed gene expression analysis using lymphoma cells in homozygousTet2 gene trap mice and CD4+ control cells.
2014-12-01 | GSE52430 | GEO
Project description:Interleukin-2-inducible T-cell kinase (ITK) has essential roles in T-cell proliferation in response to T-cell receptor stimulation and promotes Th2 and Th17 cell differentiation while suppressing Treg differentiation. ITK inhibitors have not previously been investigated for their ability to modify differentiation of either normal or malignant human CD4+ T-cells. We demonstrate that normal tonsillar CD4+ T-cell differentiation to Tfh and Th17 cells is inhibited by ITK inhibitors (ITKi) while Treg differentiation is promoted. Purified CD4+ T-cells from two cases of peripheral T-cell lymphoma demonstrated the capacity to proliferate and differentiate to Tfh, Th17 or Treg subsets in vitro. Gene expression profiling showed differences in Th-cell signature genes between normal and lymphoma cells. ITKi promoted Treg differentiation while suppressing Tfh and Th17 differentiation. The majority of CD4+ T-cells within lymph node sections did not express BCL6 compatible with the in vitro results being due to differentiation and not outgrowth already differentiated populations. The novel concept suggested by this report is that some cases of PTCL-NOS show a capacity to differentiate, which can be modified by ITKi for potential therapeutic benefit.
2018-09-26 | GSE120403 | GEO
Project description:Classic Hodgkin lymphoma (CHL) harbors a small number of Hodgkin-Reed-Sternberg (HRS) cells scattered among numerous lymphocytes. HRS cells are surrounded by distinct CD4+ T cells in a rosette-like manner. These CD4+ T cell rosettes play an important role in the tumor microenvironment (TME) of CHL. To elucidate the interaction between HRS cells and CD4+ T cell rosettes, we completed digital spatial profiling to compare the gene expression profiles of CD4+ T cell rosettes and other CD4+ T cells separated from the HRS cells. Tumor necrosis factor receptor superfamily member (TNFRSF) 4 or OX40 showed significantly higher expression in CD4+ T cell rosettes when compared with other CD4+ T cells. Programed cell death-1 (PD-1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) tended to be highly expressed in CD4+ T cell rosettes compared to other CD4+ T cells. Immunohistochemistry revealed variable expression of these immune checkpoint molecules in the CD4+ T cell rosettes. This study introduced a new pathological approach to the TME and provided deeper insight into CD4+ T cells in CHL.
2023-07-03 | GSE227013 | GEO
Project description:Peripheral T-cell lymphoma unspecified (PTCL/U), the most common form of PTCL, displays heterogeneous morphology and phenotype, poor response to treatment, and dismal prognosis. We demonstrate that PTCL/U shows a gene expression profile clearly distinct from that of normal T-cells. Comparison with the profiles of purified T-cell subpopulations [CD4+, CD8+, resting (HLA-DR-), and activated (HLA-DR+)] reveals that PTCLs/U are most closely related to activated peripheral T-lymphocytes, either CD4+ or CD8+. Interestingly, the global gene expression profile cannot be surrogated by routine CD4/CD8 immunohistochemistry. When compared with normal T-cells, PTCLs/U display deregulation of functional programs often involved in tumorigenesis (e.g. apoptosis, proliferation, cell adhesion, and matrix remodeling). Products of deregulated genes can be detected in PTCLs/U by immunohistochemistry with an ectopic, paraphysiologic or stromal location. Among others, PTCLs/U aberrantly express PDGFRA, a tyrosine-kinase receptor, whose deregulation is often related to a malignant phenotype. Notably, both phosphorylation of PDGFRA and sensitivity of cultured PTCL cells to imatinib (as well as to an inhibitor of histone-deacetylase) are found. These results, which might be extended to other rarer PTCL categories, are provided with implications for tumor pathogenesis and clinical management. Experiment Overall Design: 40 cases of Peripheral T-cell lymphoma (PTCL) were analyzed, including 28 PTCL/unspecified, 6 angioimmunoblastic (AITL) and 6 anaplastic large cell lymphoma cases (ALCL). Frozen lymph-nodes collected at diagnosis (before therapy) were used. In addition, 20 samples of normal T-cells (5 CD4+, 5 CD8+, 5 HLA-DR+, and 5 HLA-DR-) collected from peripheral blood and tonsils of healthy donors were studied. The HG U133 2.0 plus microarray (Affymetrix) was adopted.
2008-06-14 | E-GEOD-6338 | biostudies-arrayexpress
Project description:Aberrant expression of the proto-oncogene BCL6 is a driver of tumorigenesis in diffuse large B cell lymphoma (DLBCL). Mice overexpressing BCL6 from the B cell-specific immunoglobulin heavy chain μ intron promoter (Iμ-Bcl6 Tg/+ ) develop B cell lymphomas with features typical of human DLBCL. B cell lymphoma development in these mice is tightly controlled by T cells; however, the mechanisms of this immune surveillance are poorly understood. Here we show that CD4 T cells contribute to the control of lymphoproliferative disease in lymphoma-prone Iμ-Bcl6 Tg/+ mice. Furthermore, we reveal that this CD4 T-cell immuno-surveillance requires signaling by the co-stimulatory molecule, CD137 ligand (CD137L; also known as 4-1BBL), which promotes the transition of pre malignant B cells with an activated phenotype into the germinal center stage, preventing their hazardous accumulation. Thus, CD137L-mediated CD4 T cell immuno-surveillance adds another layer of protection against B-cell malignancy to that provided by CD8 T-cell cytotoxicity.
2023-01-04 | GSE196100 | GEO